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Clinical  trials  provide  the  best  evidence 
for medical decision-making. The meth-
ods for clinical trials are rapidly evolving 
in  response  to  the  needs  of  every  field, 
and clinical trials involving neurological 
disorders  face  unique  challenges.  Trials 
are  generally  launched  after  many  years 
of  painstaking  preclinical  research  and 
meticulous trial planning, and then require 
enormous efforts for successful execution. 
Despite  increasing  subspecialization  of 
neurology,  and  especially  of  neurologi-
cal research, there are undoubtedly issues 
that  are  common  to  all  and  represent 
opportunities  for  sharing  strategies  and 
resources.  Frontiers  in  Clinical  Trials  in 
Neurology (FCTN) is a new peer-reviewed, 
open-access journal launched to provide a 
broad-based forum to address these criti-
cal elements: ethical considerations, study 
design, measurement of functional status, 
and  methods  of  analysis  across  the  full 
spectrum of neurological disorders.
We challenge our colleagues to ask these 
and many other questions as they apply spe-
cifically to clinical trials in neurology:
  1.  How  can  we  improve  recruitment 
into clinical trials in neurology?
  2.  How  should  cognitively  impaired 
patients be enrolled in trials?
  3.  Who  can  consent  for  patients  with 
acute or chronic impairment?
  4.  Which patients are the most informa-
tive for a trial? Are some too mildly or 
severely affected?
  5.  How  should  we  measure  success  in 
a  neurology  trial?  How  should  we 
analyze it?
  6.  How  should  we  measure  disability 
in a neurology trial? How should we 
analyze it?
  7.  Is there a functional outcome measure 
that can be applied to most neurolo-
gical disorders?
  8.  When are non-randomized trials war-
ranted for neurological disorders?
  9.  What  is  a  clinically  meaningful  dif-
ference in outcomes for sample size 
considerations?
10.  Will  the  results  of  a  trial  be 
generalizable?
11.  Are these questions approached dif-
ferently  by  neurologists  of  various 
subspecialties?
The results of large randomized clinical 
trials  with  prominent  positive  results  will 
typically be quickly published in the most 
prominent  journals.  Neutral  and  negative 
trials  are  frequently  published  elsewhere 
and  often  with  substantially  longer  times 
until publication. Further, these large trials 
are usually preceded by decades of smaller 
pilot, proof-of-concept, surrogate endpoint, 
and early phase trials, many of which can be 
hard to find in searchable journal databases if 
published at all. Detailed protocols of upcom-
ing and ongoing trials also warrant timely 
publication. FCTN aims to provide a home 
for trial protocols and results of all types and 
sizes, with rapid publication and worldwide 
open access for researchers and clinicians.
We therefore further challenge our col-
leagues to:
1.  Promptly publish protocols for clinical 
trials in neurology.
2.  Report results as soon as possible after 
trial completion.
3.  Fully declare both successes and failures 
in neurology clinical trials.
FCTN aims to enrich the development 
and  enhance  the  dissemination  of  clini-
cal trials in neurological disorders, and to 
thereby amplify the best evidence for the 
treatment of our patients.
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